细胞凋亡抑制因子在老年慢性心力衰竭中的变化及临床意义  

The clinical significance of cell apoptosis inhibiting factor in chronic heart failure

作　　者：薛红新[1] 吴丽颖[1] 赵思义[1] 周鸿雁[1] 李伟[1] 李淑玲[1] 

机构地区：[1]安徽省淮北市人民医院干部内科,安徽淮北235000

出　　处：《中国现代医学杂志》2011年第4期435-437,共3页China Journal of Modern Medicine

摘　　要：目的观察细胞凋亡抑制因子(Fas/APO-1)在老年慢性心力衰竭(CHF)患者中的变化及血管紧张素转换酶抑制剂(ACEI)苯那普利(商品名:洛丁新)治疗对Fas/APO-1的影响。方法选择CHF患者54例,随机分为:A组(26例)即常规治疗组,给予常规抗心力衰竭治疗;B组(28例)在常规治疗基础上加用洛丁新(10 mg,qd)治疗2周,分别于治疗前后采用酶联免疫吸附双抗体夹心法(ELISA法)测定血清Fas/APO-1水平,采用超声心动图诊断方法测定左心室收缩末径(LVESD)、左心室舒张末径(LVEDD)和左心室射血分数(LVEF)等。另设健康对照组(C组)20例。结果心力衰竭患者血清Fas/APO-1水平明显高于健康对照组,洛丁新治疗2周后,较常规治疗组血清Fas/APO-1水平明显下降,LVESD和LVEDD明显减低,SV和LVEF明显升高,差异均有显著性;Fas/APO-1水平与LVEF呈负相关。结论洛丁新可明显改善CHF患者心肌重塑与心功能,其作用机制可能与降低血清Fas/APO-1水平有关。【Objective】 To observe the alterations of serum levels of Fas/APO-1 in patients with chronic heart failure（CHF） and the influence of angiotension converting enzyme inhibitors（ACEI） benazapril（Lotensin）.【Methods】 Fifty-four patients with CHF were enrolled in the study and were divided into three groups,group A（26 patients）,as conventional treatment group received conventional CHF treatment,group B（28 patients） received Lotensin plus conventional treatment for two weeks,and group C as control group.Serum levels of Fas/APO-1 were measured by ELISA.LVESD,LVEDD and LVEF were measured by echocardiogram.【Results】 Serum levels of Fas/APO-1 in patients with CHF were higher than that in control group,which were decreased in group B than that in group A after 2 week Lotensin treatment.LVESD,LVEDD were decreased and SV,LVEF were increased significantly in group B than that in group A.Serum levels of Fas/APO-1 was negatively correlated with LVEF.【Conclusions】 Lotensin may markedly improve myocardial remodeling and heart function,the mechanism may correlated with decreasing serum level of Fas/APO-1.

关 键 词：充血性心力衰竭 细胞凋亡抑制因子 苯那普利 

分 类 号：R541.6[医药卫生—心血管疾病]